<!DOCTYPE html>
<html lang="en">

<head>
  <!-- Title -->
  <title>Top News in Peptides - Q3 2025</title>

  <!-- Required Meta Tags Always Come First -->
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
  <meta http-equiv="x-ua-compatible" content="ie=edge">

  <!-- Favicon -->
  <link rel="shortcut icon" href="../assets/img/favicon.png">
  <!-- Google Fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans:300,400,600,700,800">
  <!-- CSS Global Compulsory -->
  <link rel="stylesheet" href="../assets/vendor/bootstrap/bootstrap.min.css">
  <link rel="stylesheet" href="../assets/vendor/icon-awesome/css/font-awesome.min.css">
  <link rel="stylesheet" href="../assets/vendor/icon-line-pro/style.css">
  <link rel="stylesheet" href="../assets/vendor/icon-line/css/simple-line-icons.css">
  <link rel="stylesheet" href="../assets/vendor/icon-hs/style.css">
  <link rel="stylesheet" href="../assets/vendor/animate.css">
  <link rel="stylesheet" href="../assets/vendor/fancybox/jquery.fancybox.css">
  <link rel="stylesheet" href="../assets/vendor/hs-megamenu/src/hs.megamenu.css">
  <link rel="stylesheet" href="../assets/vendor/hamburgers/hamburgers.min.css">

  <!-- CSS Unify -->
  <link rel="stylesheet" href="../assets/css/unify-core.css">
  <link rel="stylesheet" href="../assets/css/unify-components.css">
  <link rel="stylesheet" href="../assets/css/unify-globals.css">

  <!-- CSS Customization -->
  <link rel="stylesheet" href="../assets/css/custom.css">

  <!-- Paste the Mailchimp CSS link in the <head> of your HTML file -->
<link href="//cdn-images.mailchimp.com/embedcode/classic-061523.css" rel="stylesheet" type="text/css">

</head>

<body>
  <main>



      <!-- Header -->
      <header id="js-header" class="u-header u-header--static">
        <div class="u-header__section u-header__section--light g-bg-white g-transition-0_3 g-py-10">
<nav class="js-mega-menu navbar navbar-expand-lg hs-menu-initialized hs-menu-horizontal">
  <div class="container-fluid">

              <!-- Responsive Toggle Button -->
              <button class="navbar-toggler navbar-toggler-right btn g-line-height-1 g-brd-none g-pa-0 g-pos-abs g-top-minus-3 g-right-0" type="button" aria-label="Toggle navigation" aria-expanded="false" aria-controls="navBar" data-toggle="collapse" data-target="#navBar">
                <span class="hamburger hamburger--slider">
              <span class="hamburger-box">
                <span class="hamburger-inner"></span>
                </span>
                </span>
              </button>
              <!-- End Responsive Toggle Button -->
  
              <!-- Logo -->
              <a href="../index.html" class="navbar-brand d-flex me-auto">
                  <img width="46px" height="46px" src="../assets/img/favicon.png">
              </a>
                <!-- End Logo -->
  
              <!-- Navigation -->
<div class="collapse navbar-collapse align-items-center flex-sm-row g-pt-10 g-pt-5--lg" id="navBar">
  <ul class="navbar-nav text-uppercase g-pos-rel g-font-weight-600">

                  <!-- Home -->
                  <li class="nav-item  g-mx-10--lg g-mx-15--xl">
                    <a href="../index.html" class="nav-link g-py-7 g-px-0">Home</a>
                  </li>
                  <!-- End Home -->

                     <!-- Research Scale -->
                <li class="hs-has-sub-menu nav-item  g-mx-10--lg g-mx-15--xl" data-animation-in="fadeIn" data-animation-out="fadeOut">
                  <a id="nav-link-pages" class="nav-link g-py-7 g-px-0" href="../researchscale.html" aria-haspopup="true" aria-expanded="false" aria-controls="nav-submenu-pages">Research Peptide Synthesizers</a>
                  
                  <ul class="hs-sub-menu list-unstyled u-shadow-v11 g-brd-top g-brd-primary g-brd-top-2 g-min-width-220 g-mt-18 g-mt-8--lg--scrolling" id="nav-submenu-pages" aria-labelledby="nav-link-pages">
                    <!-- Pages - CSBio II -->
                    <li class="dropdown-item">
                      <a id="nav-link--pages--peptidesyn" class="nav-link" href="../csbioii.html" aria-haspopup="true" aria-expanded="false" aria-controls="nav-submenu--pages--peptidesyn">CSBio II</a>
                    </li>
                    <!-- End Pages - CSBio II  -->

                    <!-- Pages - CS136X -->
                    <li class="dropdown-item">
                      <a id="nav-link--pages--dnasyn" class="nav-link" href="../136x.html" aria-haspopup="true" aria-expanded="false" aria-controls="nav-submenu--pages--dnasyn">CS136X</a>
                    </li>
                    <!-- End Pages - CS136X -->

                    <!-- Pages - CS136M -->
                    <li class="dropdown-item">
                      <a id="nav-link--pages--purf" class="nav-link" href="../136M.html" aria-haspopup="true" aria-expanded="false" aria-controls="nav-submenu--pages--purf">CS136M</a>
                    </li>
                    <!-- End Pages - CS136M -->
                  </ul>
                </li>
    <!-- End Research Scale  -->
  
                  <!-- Pilot Scale -->
                  <li class="nav-item hs-has-sub-menu  g-mx-10--lg g-mx-15--xl" data-animation-in="fadeIn" data-animation-out="fadeOut">
                    <a id="nav-link--features" class="nav-link g-py-7 g-px-0" href="../pilotscale.html" aria-haspopup="true" aria-expanded="false" aria-controls="nav-submenu--features">Pilot Peptide Synthesizers</a>
  
                    <ul class="hs-sub-menu list-unstyled u-shadow-v11 g-brd-top g-brd-primary g-brd-top-2 g-min-width-220 g-mt-18 g-mt-8--lg--scrolling" id="nav-submenu--features" aria-labelledby="nav-link--features">
                      <!--  CS536X -->
                      <li class="dropdown-item ">
                        <a class="nav-link" href="../536x.html">CS536X</a>
                      </li>
                      <!-- End  CS536X -->
                      <!-- CS936S -->
                      <li class="dropdown-item ">
                        <a class="nav-link" href="../936s.html">CS936S</a>
                      </li>
                      <!-- End CS936S -->
                    </ul>
                  </li>
                  <!-- End Pilot Scale -->

                   <!-- Commercial Scale -->
                   <li class="nav-item g-mx-10--lg g-mx-15--xl" data-animation-in="fadeIn" data-animation-out="fadeOut">
                    <a href="../commercialscale.html" id="nav-link--features" class="nav-link g-py-7 g-px-0"  aria-haspopup="true" aria-expanded="false" aria-controls="nav-submenu--features">Commercial Peptide Synthesizers</a>
                  </li>
                  <!-- End Commercial Scale -->

                   <!-- DNA Synthesizers -->
                   <li class="nav-item g-mx-10--lg g-mx-15--xl" data-animation-in="fadeIn" data-animation-out="fadeOut">
                    <a href="../dna.html" id="nav-link--features" class="nav-link g-py-7 g-px-0"  aria-haspopup="true" aria-expanded="false" aria-controls="nav-submenu--features">DNA Synthesizers</a>
                  </li>
                  <!-- End Blog -->

  
                   <!-- Blog -->
                   <li class="nav-item g-mx-10--lg g-mx-15--xl" data-animation-in="fadeIn" data-animation-out="fadeOut">
                    <a href="../blog.html" id="nav-link--features" class="nav-link g-py-7 g-px-0"  aria-haspopup="true" aria-expanded="false" aria-controls="nav-submenu--features">Resources</a>
                  </li>
                  <!-- End Blog -->


                   <!-- About -->
                   <li class="nav-item hs-has-sub-menu  g-mx-10--lg g-mx-15--xl" data-animation-in="fadeIn" data-animation-out="fadeOut">
                    <a id="nav-link--features"  class="nav-link g-py-7 g-px-0" href="../offices.html" aria-haspopup="true" aria-expanded="false" aria-controls="nav-submenu--features">About</a>
  
                    <ul class="hs-sub-menu list-unstyled u-shadow-v11 g-brd-top g-brd-primary g-brd-top-2 g-min-width-220 g-mt-18 g-mt-8--lg--scrolling" id="nav-submenu--features" aria-labelledby="nav-link--features">
                      <!-- Contact - Offices -->
                      <li class="dropdown-item ">
                        <a class="nav-link" href="../offices.html">Company Overview</a>
                      </li>
                      <!-- End Features - Offices -->

                      <!-- Features - Careers -->
                      <li class="dropdown-item ">
                        <a class="nav-link" href="../offices.html#locations">Our Locations</a>
                      </li>
                      <!-- End Features - Careers -->

  
                    </ul>
                  </li>
                  <!-- End Contact -->

                                                           <!-- Info -->
                     <li class="nav-item g-mx-10--lg g-mx-15--xl" data-animation-in="fadeIn" data-animation-out="fadeOut">
                      <a href="../quotesynthesizer.html" id="nav-link--features" class="nav-link g-py-7 g-px-0"  aria-haspopup="true" aria-expanded="false" aria-controls="nav-submenu--features"><Strong><font color="#2f3192">Request Synthesis Equipment</Strong></font></a>
                    </li>
                    <!-- End Info -->


                </ul>
              </div>
              <!-- End Navigation -->
            </div>
          </nav>
        </div>
      </header>
      <!-- End Header -->

    <!-- Blog Single Item Banner -->
    <section class="g-bg-cover g-bg-size-cover g-bg-white-gradient-opacity-v1--after" data-bg-img-src="">
      <div class="container text-center g-pos-rel g-z-index-1 g-pb-50">
        <div class="row d-flex justify-content-center align-content-end flex-wrap g-min-height-300">
          <div class="col-lg-7 mt-auto">
            <div class="mb-5">
              <h1 class="g-color-white g-font-weight-600 g-mb-30">The Latest News in the Peptide World</h1>
              <p class="lead g-color-white-opacity-0_6">Q3 2025 Edition</p>
            </div>
          </div>
        </div>
      </div>
    </section>
    <!-- End Blog Single Item Banner -->

    <!-- Blog Single Item Info -->
    <section class="container g-pt-100 g-pb-60">
      <div class="row justify-content-center">
        <div class="col-lg-9">

          <div class="g-mb-60">

            <p><span class="d-inline-block float-left g-width-60 g-height-60 g-color-black g-font-weight-600 g-font-size-30 text-center g-pa-7 mr-2">T</span>his summer was a busy one in the peptide space. We're seeing game-changing innovations in peptide science, with drugs that can be delivered orally, act as targeted therapies, and serve as the basis for cancer vaccines and tissue regeneration scaffolds. These recent advancements are highlighting the incredible versatility of peptides, moving beyond traditional applications to address a range of diseases from rare genetic disorders to common metabolic conditions and cancers. </p>

            <p> Check out our Q3 news roundup below.</p>
          </div>
  
<div class="g-mb-60">
  <p>
    Cerapedics announced that the first patient in the U.S. has been treated with their PearlMatrix™ P-15 Peptide Enhanced Bone Graft. The P-15 Peptide, a sequence derived from Type-1 collagen, acts as a cell attachment factor to promote bone regeneration by providing numerous attachment sites for bone-forming cells. Cerapedics recently received FDA approval for the P-15 Peptide.
  </p>
  <a class="g-font-size-13" href="https://www.cerapedics.com/news/cerapedics-announces-first-us-patient-treated-pearlmatrixtm-p-15-peptide-enhanced-bone-graft">Read more...</a>
</div>

<div class="g-mb-60">
  <p>Amphix Bio has received FDA Orphan Drug Designation for its therapeutic, AMFX-200, which utilizes a new technology platform called Supramolecular Therapeutic Peptides (STPs). These peptides are designed to act as both a drug to activate cell receptors and a physical scaffold to support tissue regeneration, with preclinical studies showing they can help restore motor function after a single injection.

  </p>
  <a class="g-font-size-13" href="https://www.prnewswire.com/news-releases/amphix-bio-receives-fda-orphan-drug-designation-for-neural-regeneration-therapeutic-to-treat-acute-spinal-cord-injury-302506799.html">Read more...</a>
</div>

<div class="g-mb-60">
  <p>
    TerSera Therapeutics presented real-world data on prescription patterns for ziconotide (PRIALT®), a non-opioid pain medication derived from a marine snail peptide. The data shows a positive shift in clinical practice toward using ziconotide as a monotherapy and at lower starting doses, aligning with established guidelines for this peptide-based drug.

  </p>
  <a class="g-font-size-13" href="https://www.biospace.com/press-releases/tersera-therapeutics-to-present-real-world-data-on-intrathecal-ziconotide-prialt-prescription-patterns-at-aspn-2025">Read more...</a>
</div>

<div class="g-mb-60">
  <p>
    EndoCyclic Therapeutics was awarded a "Perfect 10" NIH grant for ENDO-205, a non-hormonal therapeutic for endometriosis that uses a novel pH-sensitive peptide mechanism. The therapeutic  selectively eliminates lesions at the disease site while leaving healthy tissue untouched, potentially offering the first-ever disease-modifying therapy for endometriosis.

  </p>
  <a class="g-font-size-13" href="https://www.prnewswire.com/news-releases/endocyclic-therapeutics-awarded-rare-nih-perfect-10-grant-for-endometriosis-therapeutic-302557004.html">Read more...</a>
</div>

<div class="g-mb-60">
  <p>
    NervGen Pharma's therapeutic peptide, NVG-291-R, a rodent variant of NVG-291, has shown significant functional recovery in preclinical studies of traumatic hearing loss and peripheral nerve injury.The peptide can restore hearing and promote axonal regeneration by targeting nervous system repair.
  </p>
  <a class="g-font-size-13" href="https://nervgen.com/nervgen-pharmas-nvg-291-r-demonstrates-significant-functional-recovery-in-department-of-defense-sponsored-preclinical-models-of-traumatic-hearing-loss-and-peripheral-nerve-injury/">Read more...</a>
</div>

<div class="g-mb-60">
  <p>
    Merck’s Enlicitide, a macrocyclic peptide that inhibits PCSK9, was effective in reducing LDL cholesterol in adults with hyperlipidemia in Phase 3 trials. 
  </p>
  <a class="g-font-size-13" href="https://www.fiercebiotech.com/biotech/mercks-leader-oral-pcsk9-inhibitor-race-reduces-cholesterol-pair-phase-3-trials">Read more...</a>
</div>

<div class="g-mb-60">
  <p>
    Protagonist Therapeutics announced that its hepcidin-mimetic peptide, Rusfertide, has been granted Breakthrough Therapy Designation by the FDA for the treatment of erythrocytosis in patients with polycythemia vera. The designation was based on positive data from a Phase 3 study, which demonstrated that Rusfertide effectively controlled hematocrit levels, reduced the need for phlebotomy, and improved patient-reported fatigue.

  </p>
  <a class="g-font-size-13" href="https://www.biospace.com/press-releases/rusfertide-receives-breakthrough-therapy-designation-for-treatment-of-erythrocytosis-in-patients-with-polycythemia-vera">Read more...</a>
</div>

<div class="g-mb-60">
  <p>
    ReAlta Life Sciences was granted Orphan Drug Designation by the European Medicines Agency (EMA) for RLS-0071 (Pegtarazimod), a synthetic peptide, to treat graft-versus-host disease (GvHD). The therapeutic peptide works by inhibiting inflammatory pathways driven by neutrophils which  are responsible for the tissue damage that occurs when transplanted immune cells attack the patient.

  </p>
  <a class="g-font-size-13" href="https://www.biospace.com/press-releases/realta-life-sciences-receives-ema-orphan-drug-designation-for-rls-0071-pegtarazimod-for-the-treatment-of-graft-versus-host-disease">Read more...</a>
</div>

<div class="g-mb-60">
  <p>
   Rein Therapeutics' lead drug candidate, LTI-03, is a peptide-based therapy for Idiopathic Pulmonary Fibrosis (IPF). Recently published data showed that LTI-03 effectively reduced multiple scarring pathways and lowered collagen production in diseased patient lung tissue without causing cell damage unlike other approved drugs.

  </p>
  <a class="g-font-size-13" href="https://ir.reintx.com/news-releases/news-release-details/rein-therapeutics-announces-publication-new-translational-data
">Read more...</a>
</div>

<div class="g-mb-60">
  <p>
    Inotrem's drug candidate, Nangibotide, is an immunomodulatory peptide being developed to treat septic shock. The peptide inhibits the TREM-1 pathway, responsible for amplifying the body's inflammatory response. Nanbigotide has shown promise in improving outcomes for high-risk patients.

  </p>
  <a class="g-font-size-13" href="https://www.biospace.com/press-releases/inotrem-unveils-game-changing-precision-medicine-strategy-for-nangibotide-clinical-development-in-septic-shock">Read more...</a>
</div>

    
<div class="g-mb-60">
  <p>
  OPKO Health and Entera Bio announced that their abstract on an oral GLP-2 tablet for treating Short Bowel Syndrome has been selected for the 2025 ESPEN Congress. The new tablet combines a long-acting GLP-2 agonist peptide from OPKO with Entera's N-Tab™ technology to offer a convenient oral alternative to the current daily injectable therapy.


  </p>
  <a class="g-font-size-13" href="https://www.biospace.com/press-releases/opko-health-and-entera-bio-announce-abstract-on-pk-pd-of-oral-glp-2-tablet-for-the-treatment-of-short-bowel-syndrome-selected-for-2025-espen-congress">Read more...</a>
</div>

<div class="g-mb-60">
  <p>
  Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-01435, a long-acting peptide that acts as a corticotropin-releasing factor type 1 receptor antagonist. The investigational peptide is being developed as a potential treatment for congenital adrenal hyperplasia (CAH), with the goal of improving androgen control and enabling lower glucocorticoid dosing.
  </p>
  <a class="g-font-size-13" href="https://www.biospace.com/press-releases/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-nbip-01435-a-long-acting-corticotropin-releasing-factor-type-1-receptor-antagonist">Read more...</a>
</div>

<div class="g-mb-60">
  <p>
   In a Phase 1 clinical trial, a new pancreatic cancer vaccine, which uses peptides to train the immune system's T cells to recognize and destroy cancer cells, showed promise in preventing recurrence. The vaccine, which targets the common KRAS gene mutation, led to durable immune responses and longer relapse-free survival in high-risk patients.

  </p>
  <a class="g-font-size-13" href="https://www.nbcnews.com/health/cancer/pancreatic-cancer-vaccine-prevents-recurrence-phase-1-clinical-trial-rcna223980">Read more...</a>
</div>

<div class="g-mb-60">
  <p>
   ProteinQure announced that it has dosed the first patient in a Phase I clinical trial for its novel peptide therapeutic, PQ203, for patients with advanced metastatic solid tumors. The drug was designed using ProteinQure’s AI platform, and works by targeting the Sortilin receptor. PQ203 has shown promise in preclinical models of Triple Negative Breast Cancer (TNBC).
  </p>
  <a class="g-font-size-13" href="https://www.proteinqure.com/proteinqure-announces-first-patient-dosed-in-phase-i-clinical-trial-of-pq203-in-advanced-metastatic-cancer/">Read more...</a>
</div>



    
<div class="g-mb-60">
  <p>
    Greenwich LifeSciences announced that its immunotherapy product, GLSI-100, has received FDA Fast Track designation for treating HER2-positive breast cancer. The product is based on the GP2 peptide, a nine-amino-acid segment of the HER2 protein, which has shown an 80% reduction in metastatic breast cancer recurrence in previous studies.

  </p>
  <a class="g-font-size-13" href="https://investor.greenwichlifesciences.com/news-events/press-releases/detail/102/us-fda-fast-track-designation">Read more...</a>
</div>

<div class="g-mb-60">
  <p>Avacta's drug, AVA6000, is a peptide drug conjugate designed to be activated specifically within the tumor microenvironment. The data presented at the 2025 ESMO Congress shows that the drug is well-tolerated with fewer side effects than conventional chemotherapy, while also demonstrating promising signs of efficacy, particularly in patients with salivary gland cancers.
  </p>
  <a class="g-font-size-13" href="https://avacta.com/avacta-to-present-new-fap-dox-ava6000-data-at-the-european-society-for-medical-oncology-esmo-congress/">Read more...</a>
</div>

<div class="g-mb-60">
  <p>Johnson & Johnson has submitted an application for FDA approval of Icotrokinra, a novel oral peptide that selectively blocks the IL-23 receptor to treat plaque psoriasis. In clinical trials, the drug demonstrated superiority to other treatments and a favorable safety profile, with potential to become a new standard of care.

  </p>
  <a class="g-font-size-13" href="https://www.biospace.com/press-releases/johnson-johnson-seeks-first-icotrokinra-u-s-fda-approval-aiming-to-revolutionize-treatment-paradigm-for-adults-and-adolescents-with-plaque-psoriasis">Read more...</a>
</div>

<div class="g-mb-60">
  <p>Altimmune has initiated a Phase 2 trial for Pemvidutide, a peptide-based drug that acts as a dual receptor agonist for GLP-1 and glucagon. The trial, called RESTORE, is evaluating the drug's efficacy and safety in treating alcohol-associated liver disease by focusing on its ability to reduce liver stiffness and fat while also promoting weight loss.

  </p>
  <a class="g-font-size-13" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-initiation-restore-phase-2-trial-evaluating">Read more...</a>
</div>

<div class="g-mb-60">
  <p>In a major win for obesity treatment, the peptide-based dual receptor agonist, Zepbound KwikPen (tirzepatide injection), is now approved and available in Canada. The Zepabound KwikPen uses peptides to activate GIP and GLP-1 hormone receptors, offering a new approach to managing obesity by mimicking the body's natural hunger and satiety signals. 
  </p>
  <a class="g-font-size-13" href="https://www.biospace.com/press-releases/zepbound-kwikpen-tirzepatide-injection-the-first-and-only-dual-receptor-agonist-for-the-treatment-of-obesity-now-approved-and-available-in-canada">Read more...</a>
</div>

<div class="g-mb-60">
  <p>Novo Nordisk's oral semaglutide has received EU approval to reduce cardiovascular death, heart attack, and stroke in people with type 2 diabetes. This marks a significant milestone as it's the first and only oral GLP-1 RA (glucagon-like peptide 1 receptor agonist) to offer this proven cardiovascular benefit. 
  </p>
  <a class="g-font-size-13" href="https://www.biospace.com/press-releases/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke">Read more...</a>
</div>

<div class="g-mb-60">
  <p>Novo Nordisk's oral Wegovy is putting a spotlight on the viability of high-dose peptides for drug development. The drug demonstrates that peptides, which typically break down in the stomach, can be delivered orally through the use of an absorption enhancer, paving the way for more convenient treatments.
  </p>
  <a class="g-font-size-13" href="https://www.biospace.com/drug-development/oral-wegovys-pending-approval-puts-spotlight-on-viability-of-high-dose-peptides">Read more...</a>
</div>


        </div>
      </div>
    </section>
    <!-- End Blog Single Item Info -->


          <!-- Social Icons -->
          <div class="text-center">
            <h3 class="h6 g-color-black g-font-weight-600 text-uppercase mb-3">Share:</h3>
            <ul class="list-inline g-mb-60">
              <li class="list-inline-item g-mx-2">
                <a class="u-icon-v1 u-icon-slide-up--hover g-color-gray-dark-v4 g-color-linkedin--hover" href="https://www.linkedin.com/sharing/share-offsite/?url=https://www.csbio.com/monthly/news-feb2024">
                  <i class="g-font-size-default g-line-height-1 u-icon__elem-regular fa fa-linkedin"></i>
                  <i class="g-font-size-default g-line-height-0_8 u-icon__elem-hover fa fa-linkedin"></i>
                </a>
              </li>
            </ul>
          </div>
          <!-- End Social Icons -->
        </div>
      </div>
    </section>
    <!-- End Blog Single Item Author -->

          <!-- Call to Action -->

<div class="shortcode-html">
    <section class="g-color-white g-bg-primary g-pa-40">
        <div class="container">
            <div class="row">
                <div class="col-md-8 align-self-center">
                    <h2 class="h3 text-uppercase g-font-weight-300 g-mb-20 g-mb-0--md">Get the <strong>top 10</strong> highlights monthly in your inbox
                    </h2>
                </div>

                <div class="col-md-4 align-self-center">
                    <!-- Begin Mailchimp Signup Form -->
                    <div id="mc_embed_signup">
                        <form action="https://csbio.us21.list-manage.com/subscribe/post?u=24a6d0fd3c6e9baad298d302c&amp;id=a5b48c4200&amp;f_id=003dece6f0" 
                              method="post" 
                              id="mc-embedded-subscribe-form" 
                              name="mc-embedded-subscribe-form" 
                              class="validate" 
                              target="_blank">

                            <div class="input-group g-brd-white--focus">
                                <input class="form-control form-control-lg g-font-size-default g-placeholder-white g-color-white g-bg-transparent g-bg-transparent--focus g-brd-white rounded-0 required email" 
                                       name="EMAIL" 
                                       type="email" 
                                       id="mce-EMAIL" 
                                       required="" 
                                       placeholder="Enter your email...">
                                <div class="input-group-append">
                                    <input type="submit" value="Subscribe" name="subscribe" id="mc-embedded-subscribe" class="button input-group-text g-color-white g-bg-transparent g-brd-white rounded-0">
                                </div>
                            </div>
                        </form>
                    </div>
                    <!--End mc_embed_signup-->
                </div>
            </div>
        </div>
    </section>
</div>
            
    <!-- End Call to Action -->
  


      <!-- Footer -->
      <div id="contacts-section" class="g-bg-black-opacity-0_9 g-color-white-opacity-0_8 g-py-60">
        <div class="container">
          <div class="row">
            <!-- Footer Content -->
            <div class="col-md-3 g-mb-40 g-mb-0--lg">
              <div class="u-heading-v2-3--bottom g-brd-white-opacity-0_8 g-mb-20">
                <h2 class="u-heading-v2__title h6 text-uppercase mb-0">About Us</h2>
              </div>
  
              <p>CSBio is a leading peptide instrumentation manufacturing company located in Silicon Valley, California. <br> <br>CSBio provides research scale peptide synthesizers, pilot scale peptide synthesizers, commerical scale peptide synthesizers, and DNA/RNA oligonucleotide synthesizers.</p>
            </div>
            <!-- End Footer Content -->
  
            <!-- Footer Content -->
  
  
            <!-- Footer Content -->
            <div class="col-md-3 g-mb-40 g-mb-0--lg">
              <div class="u-heading-v2-3--bottom g-brd-white-opacity-0_8 g-mb-20">
                <h2 class="u-heading-v2__title h6 text-uppercase mb-0">Links</h2>
              </div>
  
              <nav class="text-uppercase1">
                <ul class="list-unstyled g-mt-minus-10 mb-0">
                  <li class="g-pos-rel g-brd-bottom g-brd-white-opacity-0_1 g-py-10">
                    <h4 class="h6 g-pr-20 mb-0">
                  <a class="g-color-white-opacity-0_8 g-color-white--hover" href="../index.html">Home</a>
                  <i class="fa fa-angle-right g-absolute-centered--y g-right-0"></i>
                </h4>
                  </li>
                  <li class="g-pos-rel g-brd-bottom g-brd-white-opacity-0_1 g-py-10">
                    <h4 class="h6 g-pr-20 mb-0">
                  <a class="g-color-white-opacity-0_8 g-color-white--hover" href="../researchscale.html">Research Scale Synthesizers</a>
                  <i class="fa fa-angle-right g-absolute-centered--y g-right-0"></i>
                </h4>
                  </li>
                                    <li class="g-pos-rel g-brd-bottom g-brd-white-opacity-0_1 g-py-10">
                    <h4 class="h6 g-pr-20 mb-0">
                  <a class="g-color-white-opacity-0_8 g-color-white--hover" href="../pilotscale.html">Pilot Scale Synthesizers</a>
                  <i class="fa fa-angle-right g-absolute-centered--y g-right-0"></i>
                </h4>
                  </li>
                                    <li class="g-pos-rel g-brd-bottom g-brd-white-opacity-0_1 g-py-10">
                    <h4 class="h6 g-pr-20 mb-0">
                  <a class="g-color-white-opacity-0_8 g-color-white--hover" href="../commercialscale.html">Commercial Scale Synthesizers</a>
                  <i class="fa fa-angle-right g-absolute-centered--y g-right-0"></i>
                </h4>
                  </li>
                                    <li class="g-pos-rel g-brd-bottom g-brd-white-opacity-0_1 g-py-10">
                    <h4 class="h6 g-pr-20 mb-0">
                  <a class="g-color-white-opacity-0_8 g-color-white--hover" href="../dna.html">DNA Scale Synthesizers</a>
                  <i class="fa fa-angle-right g-absolute-centered--y g-right-0"></i>
                </h4>
                  </li>
                  <li class="g-pos-rel g-brd-bottom g-brd-white-opacity-0_1 g-py-10">
                    <h4 class="h6 g-pr-20 mb-0">
                  <a class="g-color-white-opacity-0_8 g-color-white--hover" href="../blog.html">Resources</a>
                  <i class="fa fa-angle-right g-absolute-centered--y g-right-0"></i>
                </h4>
                  </li>
                  <li class="g-pos-rel g-py-10">
                    <h4 class="h6 g-pr-20 mb-0">
                  <a class="g-color-white-opacity-0_8 g-color-white--hover" href="../offices.html">About</a>
                  <i class="fa fa-angle-right g-absolute-centered--y g-right-0"></i>
                </h4>
                  </li>
                </ul>
              </nav>
            </div>
            <!-- End Footer Content -->
  
            <!-- Footer Content -->

                                    <div class="col-md-3">
              <div class="u-heading-v2-3--bottom g-brd-white-opacity-0_8 g-mb-20">
                <h2 class="u-heading-v2__title h6 text-uppercase mb-0"> Contact</h2>
              </div>
  
              <address class="g-bg-no-repeat g-font-size-12 mb-0" style="background-image: url();">
            <!-- Location -->
            <div class="d-flex g-mb-20">
              <div class="g-mr-10">
                <span class="u-icon-v3 u-icon-size--xs g-bg-white-opacity-0_1 g-color-white-opacity-0_6">
                  <i class="fa fa-map-marker"></i>
                </span>
              </div>
              <p class="mb-0">915 Linda Vista Ave<br>Mountain View, CA, 94043</p>
            </div>
            <!-- End Location -->
  
            <!-- Phone -->
            <div class="d-flex g-mb-20">
              <div class="g-mr-10">
                <span class="u-icon-v3 u-icon-size--xs g-bg-white-opacity-0_1 g-color-white-opacity-0_6">
                  <i class="fa fa-phone"></i>
                </span>
              </div>
              <p class="mb-0"> <br> +1-650-525-6200<br> </p>
            </div>
            <!-- End Phone -->
  
            <!-- Email and Website -->
            <div class="d-flex g-mb-20">
              <div class="g-mr-10">
                <span class="u-icon-v3 u-icon-size--xs g-bg-white-opacity-0_1 g-color-white-opacity-0_6">
                  <i class="fa fa-globe"></i>
                </span>
              </div>
              <p class="mb-0">
                <a class="g-color-white-opacity-0_8 g-color-white--hover" href="mailto:instrument@csbio.com">instrument@csbio.com</a>
              </p>
            </div>
            <!-- End Email and Website -->
          </address>
            </div>


            <!-- End Footer Content -->
          </div>
        </div>
      </div>
      <!-- End Footer -->
  
      <!-- Copyright Footer -->
      <footer class="g-bg-gray-dark-v1 g-color-white-opacity-0_8 g-py-20">
        <div class="container">
          <div class="row">
            <div class="col-md-8 text-center text-md-left g-mb-10 g-mb-0--md">
              <div class="d-lg-flex">
                <small class="d-block g-font-size-default g-mr-10 g-mb-10 g-mb-0--md">2026 &copy; All Rights Reserved.</small>     
              </div>
            </div>
          </div>
        </div>
      </footer>
      <!-- End Copyright Footer -->

    <a class="js-go-to u-go-to-v1" href="#" data-type="fixed" data-position='{
     "bottom": 15,
     "right": 15
   }' data-offset-top="400" data-compensation="#js-header" data-show-effect="zoomIn">
      <i class="hs-icon hs-icon-arrow-top"></i>
    </a>
  </main>

  <div class="u-outer-spaces-helper"></div>

      <!-- Google Analytics -->
      <script>
      window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;
      ga('create', 'UA-62852370-1', 'auto');
      ga('send', 'pageview');
      </script>
      <script async src='https://www.google-analytics.com/analytics.js'></script>
      <!-- End Google Analytics -->

  <!-- JS Global Compulsory -->
  <script src="../assets/vendor/jquery/jquery.min.js"></script>
  <script src="../assets/vendor/jquery-migrate/jquery-migrate.min.js"></script>
  <script src="../assets/vendor/popper.js/popper.min.js"></script>
  <script src="../assets/vendor/bootstrap/bootstrap.min.js"></script>


  <!-- JS Implementing Plugins -->
  <script src="../assets/vendor/hs-megamenu/src/hs.megamenu.js"></script>
  <script src="../assets/vendor/fancybox/jquery.fancybox.min.js"></script>

  <!-- JS Unify -->
  <script src="../assets/js/hs.core.js"></script>
  <script src="../assets/js/components/hs.header.js"></script>
  <script src="../assets/js/helpers/hs.hamburgers.js"></script>
  <script src="../assets/js/components/hs.tabs.js"></script>
  <script src="../assets/js/components/hs.popup.js"></script>
  <script src="../assets/js/components/hs.go-to.js"></script>

  <!-- JS Customization -->
  <script src="../assets/js/custom.js"></script>

  <!-- JS Plugins Init. -->
  <script>
    $(document).on('ready', function () {
        // initialization of tabs
        $.HSCore.components.HSTabs.init('[role="tablist"]');

        // initialization of popups
        $.HSCore.components.HSPopup.init('.js-fancybox');

        // initialization of go to
        $.HSCore.components.HSGoTo.init('.js-go-to');
      });

      $(window).on('load', function () {
        // initialization of header
        $.HSCore.components.HSHeader.init($('#js-header'));
        $.HSCore.helpers.HSHamburgers.init('.hamburger');

        // initialization of HSMegaMenu component
        $('.js-mega-menu').HSMegaMenu({
          event: 'hover',
          pageContainer: $('.container'),
          breakpoint: 991
        });
      });

      $(window).on('resize', function () {
        setTimeout(function () {
          $.HSCore.components.HSTabs.init('[role="tablist"]');
        }, 200);
      });
  </script>


<!-- Paste the Mailchimp JS script at the bottom of your HTML file, before the closing </body> tag -->
<script type="text/javascript" src="//s3.amazonaws.com/downloads.mailchimp.com/js/mc-validate.js"></script>
<script type="text/javascript">
    (function($) {
        window.fnames = new Array(); 
        window.ftypes = new Array();
        fnames[0]='EMAIL';ftypes[0]='email';
        //... Add other fields if necessary
    }(jQuery));
    var $mcj = jQuery.noConflict(true);
</script>




</body>

</html>
